Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae Type b Adsorbed (DTaP-HB-IPV-Hib) 

INFANRIX hexa®  Supplier: GlaxoSmithKline Inc.

INDICATIONS:
- Routine infant schedule.
- Infants at high risk of hepatitis B who have received a birth dose of HBlg and/or hepatitis B vaccine.
- Completion of primary series of INFANRIX hexa® before 7 years of age.
- Select special populations as indicated in Part 2 – Immunization of Special Populations.

INFANRIX hexa® is not routinely indicated for those 7 years of age and older.

DOSES AND SCHEDULE: A, B

Routine infant schedule and high risk infants: 3 doses given as 0.5 mL IM at 2, 4, and 6 months of age.

Unimmunized or incompletely immunized infants and children less than 7 years of age: up to 3 doses given as 0.5 mL IM, separated by 8 weeks.

Select special populations: as indicated in Part 2 – Immunization of Special Populations.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES:
None using this product. C

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of diphtheria, tetanus, pertussis, hepatitis B, inactivated polio or Haemophilus influenzae type b-containing vaccine or to any component of INFANRIX hexa®.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a tetanus-containing vaccine.

A The primary series of 3 doses of DTaP-containing vaccine should be completed with the product from the same manufacturer whenever possible. However, if the product used for prior dose(s) is unknown or unavailable from BCCDC Pharmacy, the primary series may be completed with an alternative combination vaccine from a different manufacturer.

B INFANRIX hexa® can be used as a booster dose for those under 7 years of age who require protection against tetanus, diphtheria, pertussis, polio, Hib and hepatitis B, regardless of which product was used for the primary series.

C Refer to Part 1 – Immunization Schedules for information regarding booster doses using the age appropriate tetanus and diphtheria-containing vaccines.
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae Type b Adsorbed (DTaP-HB-IPV-Hib)
INFANRIX hexa®       Supplier: GlaxoSmithKline Inc.

PRODUCT COMPONENTS:
Potential allergens: neomycin sulphate, polymyxin B sulphate, polysorbate 80.
Other components: lactose, aluminum hydroxide, aluminum phosphate, formaldehyde, polysorbate 20, M199, potassium chloride, disodium phosphate, monopotassium phosphate, glycine, yeast protein.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
• INFANRIX hexa® contains only a single dose of HB vaccine (as ENGERIX®-B) and is not indicated for infants and children requiring a Hepatitis B Vaccine Higher Dose Schedule.
• A hypotonic-hyporesponsive episode (HHE) following a prior dose of DTaP-containing vaccine is not a contraindication to future immunization and continued immunization with all antigens is recommended.
• While the number of Hib doses varies with age of presentation, INFANRIX hexa® should be administered using the indicated schedules even if an ‘extra’ dose of Hib is administered for age.
• Any dose(s) of oral polio vaccine (OPV) received on or after April 1, 2016 will not be considered as a valid dose within the routine BC immunization schedule. For more information, see Part 4 – Biological Products, Polio Vaccine, Special Considerations.

ADVERSE EVENTS:
Local: soreness, redness, swelling.
Systemic: fever, anorexia, restlessness, irritability, persistent or unusual crying, vomiting, diarrhea.